Cargando…
The Potential Use of Metabolic Cofactors in Treatment of NAFLD
Non-alcoholic fatty liver disease (NAFLD) is caused by the imbalance between lipid deposition and lipid removal from the liver, and its global prevalence continues to increase dramatically. NAFLD encompasses a spectrum of pathological conditions including simple steatosis and non-alcoholic steatohep...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682907/ https://www.ncbi.nlm.nih.gov/pubmed/31336926 http://dx.doi.org/10.3390/nu11071578 |
_version_ | 1783441973962604544 |
---|---|
author | Mardinoglu, Adil Ural, Dilek Zeybel, Mujdat Yuksel, Hatice Hilal Uhlén, Mathias Borén, Jan |
author_facet | Mardinoglu, Adil Ural, Dilek Zeybel, Mujdat Yuksel, Hatice Hilal Uhlén, Mathias Borén, Jan |
author_sort | Mardinoglu, Adil |
collection | PubMed |
description | Non-alcoholic fatty liver disease (NAFLD) is caused by the imbalance between lipid deposition and lipid removal from the liver, and its global prevalence continues to increase dramatically. NAFLD encompasses a spectrum of pathological conditions including simple steatosis and non-alcoholic steatohepatitis (NASH), which can progress to cirrhosis and liver cancer. Even though there is a multi-disciplinary effort for development of a treatment strategy for NAFLD, there is not an approved effective medication available. Single or combined metabolic cofactors can be supplemented to boost the metabolic processes altered in NAFLD. Here, we review the dosage and usage of metabolic cofactors including l-carnitine, Nicotinamide riboside (NR), l-serine, and N-acetyl-l-cysteine (NAC) in human clinical studies to improve the altered biological functions associated with different human diseases. We also discuss the potential use of these substances in treatment of NAFLD and other metabolic diseases including neurodegenerative and cardiovascular diseases of which pathogenesis is linked to mitochondrial dysfunction. |
format | Online Article Text |
id | pubmed-6682907 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-66829072019-08-09 The Potential Use of Metabolic Cofactors in Treatment of NAFLD Mardinoglu, Adil Ural, Dilek Zeybel, Mujdat Yuksel, Hatice Hilal Uhlén, Mathias Borén, Jan Nutrients Review Non-alcoholic fatty liver disease (NAFLD) is caused by the imbalance between lipid deposition and lipid removal from the liver, and its global prevalence continues to increase dramatically. NAFLD encompasses a spectrum of pathological conditions including simple steatosis and non-alcoholic steatohepatitis (NASH), which can progress to cirrhosis and liver cancer. Even though there is a multi-disciplinary effort for development of a treatment strategy for NAFLD, there is not an approved effective medication available. Single or combined metabolic cofactors can be supplemented to boost the metabolic processes altered in NAFLD. Here, we review the dosage and usage of metabolic cofactors including l-carnitine, Nicotinamide riboside (NR), l-serine, and N-acetyl-l-cysteine (NAC) in human clinical studies to improve the altered biological functions associated with different human diseases. We also discuss the potential use of these substances in treatment of NAFLD and other metabolic diseases including neurodegenerative and cardiovascular diseases of which pathogenesis is linked to mitochondrial dysfunction. MDPI 2019-07-12 /pmc/articles/PMC6682907/ /pubmed/31336926 http://dx.doi.org/10.3390/nu11071578 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Mardinoglu, Adil Ural, Dilek Zeybel, Mujdat Yuksel, Hatice Hilal Uhlén, Mathias Borén, Jan The Potential Use of Metabolic Cofactors in Treatment of NAFLD |
title | The Potential Use of Metabolic Cofactors in Treatment of NAFLD |
title_full | The Potential Use of Metabolic Cofactors in Treatment of NAFLD |
title_fullStr | The Potential Use of Metabolic Cofactors in Treatment of NAFLD |
title_full_unstemmed | The Potential Use of Metabolic Cofactors in Treatment of NAFLD |
title_short | The Potential Use of Metabolic Cofactors in Treatment of NAFLD |
title_sort | potential use of metabolic cofactors in treatment of nafld |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682907/ https://www.ncbi.nlm.nih.gov/pubmed/31336926 http://dx.doi.org/10.3390/nu11071578 |
work_keys_str_mv | AT mardinogluadil thepotentialuseofmetaboliccofactorsintreatmentofnafld AT uraldilek thepotentialuseofmetaboliccofactorsintreatmentofnafld AT zeybelmujdat thepotentialuseofmetaboliccofactorsintreatmentofnafld AT yukselhaticehilal thepotentialuseofmetaboliccofactorsintreatmentofnafld AT uhlenmathias thepotentialuseofmetaboliccofactorsintreatmentofnafld AT borenjan thepotentialuseofmetaboliccofactorsintreatmentofnafld AT mardinogluadil potentialuseofmetaboliccofactorsintreatmentofnafld AT uraldilek potentialuseofmetaboliccofactorsintreatmentofnafld AT zeybelmujdat potentialuseofmetaboliccofactorsintreatmentofnafld AT yukselhaticehilal potentialuseofmetaboliccofactorsintreatmentofnafld AT uhlenmathias potentialuseofmetaboliccofactorsintreatmentofnafld AT borenjan potentialuseofmetaboliccofactorsintreatmentofnafld |